Please provide your email address to receive an email when new articles are posted on . Myopia is the most common refractive error in the United States and globally ...

Please provide your email address to receive an email when new articles are posted on . In 1980, while helping the late George O. Waring III prepare the grant application for the soon to be initiated ...

Rates of childhood myopia have increased steadily over the past decade, with eye care professionals reporting that vision changes are appearing at younger ages. Astigmatism, which affects how light ...

Visit NAP.edu/10766 to get more information about this book, to buy it in print, or to download it as a free PDF. Myopia, commonly called nearsightedness, is a ...

SAN DIEGO--(BUSINESS WIRE)--Sydnexis, Inc., a clinical stage biopharmaceutical company with a proprietary formulation of low dose atropine for the treatment of progressive myopia, today announced the ...

Comprehensive analyses identified children aged 3 to 12 years and fast progressors with mild to moderate myopia as the populations with greatest treatment benefit Data demonstrated consistent effects ...

Myopia, more commonly known as nearsightedness, is a condition due to the physical length of the eye being relatively too long for its refractive components. Despite its strong family trait, juvenile ...

SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems Inc. (“iVeena”), a biopharmaceutical company with a developmental product in pediatric myopia is pleased to announce that Dr. Sarah Molokhia, ...

Eyenovia, Inc. EYEN announced the decision to terminate a phase III study evaluating its investigational drug-device product, MicroPine, as a potential treatment for pediatric progressive myopia.

Explore the myopia pandemic's impact on children's vision and lifestyle changes during Myopia Awareness Week, May 18-24.

Suggested Citation: "1 Introduction." National Academies of Sciences, Engineering, and Medicine. 2024. Myopia: Causes, Prevention, and Treatment of an Increasingly ...

Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced it will present new data related to ...